Approved by the EMA in 2021, roxadustat has advantages over traditional treatments with erythropoietin-stimulating agents as it more accurately replicates a physiological state of hypoxemia, which also regulates iron beneficially in managing renal anemia in patients bearing CKD [26]. The gene discussed is EPO; the disease is chronic kidney disease.